China's Leading CRO WuXi Looks To Utilize Manufacturing Capacity With Telaprevir

SHANGHAI - Leading Chinese contract research organization WuXi PharmaTech Co., Ltd. recorded a strong quarter with revenue up 16% over the same period last year to $93.6 million, and the company is readying itself for big increases in its manufacturing business thanks to large-scale contracts generated from discovery deals